Niagen Bioscience (NAGE) Receivables - Other (2013 - 2023)

Niagen Bioscience (NAGE) has 9 years of Receivables - Other data on file, last reported at $3.5 million in Q1 2023.

• Receivables - Other for Q1 2023 came in at $3.5 million, up 52.17% year-over-year; the trailing twelve-month figure through Mar 2023 was $3.5 million (up 52.17% YoY), and the FY2022 annual result was $3.1 million, up 47.62% from the prior year.
• Receivables - Other advanced to $3.5 million in Q1 2023 per NAGE's latest filing, from $3.1 million in the prior quarter.
• Over five years, Receivables - Other peaked at $3.5 million in Q1 2023 and troughed at $800000.0 in Q4 2019.
• A 5-year average of $1.9 million and a median of $1.9 million in 2019 frame the typical range for Receivables - Other.
• The sharpest annual moves came in 2019 and 2022: Receivables - Other jumped 171.43% in 2019, then sank 40.91% in 2022.
• A 5-year view of Receivables - Other shows it stood at $800000.0 in 2019, then grew by 12.5% to $900000.0 in 2020, then surged by 133.33% to $2.1 million in 2021, then jumped by 47.62% to $3.1 million in 2022, then climbed by 12.9% to $3.5 million in 2023.
• Business Quant data shows NAGE's Receivables - Other at $3.5 million in Q1 2023, $3.1 million in Q4 2022, and $2.4 million in Q3 2022.